(RTTNews) - Moderna, Inc (MRNA) shares suffered their steepest decline since August after leaked late-stage trial results for its personalized melanoma vaccine showed a smaller risk reduction than an earlier study.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.